 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
3 News |  |
- Actoferon (IFN beta1b biosimilar) / Actoverco, AMEGA Biotech, Betaseron (IFN-β-1b) / Bayer
A Randomized, Double-blind Controlled Clinical Study to Determine the Effectiveness, Safety and Tolerability of Actoferon® Compared to Betaferon® in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) (ePoster Area) - Oct 18, 2022 - Abstract #ECTRIMS2022ECTRIMS_1719;
There was no significant difference between Betaferon®and Actoferon®in aspects of efficacy, safety and tolerability. This study showed the non-inferiority of Actoferon®to Betaferon®.